|
gptkbp:instanceOf
|
long-acting insulin
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10AE05
|
|
gptkbp:brand
|
gptkb:Levemir
|
|
gptkbp:CASNumber
|
169148-63-4
|
|
gptkbp:developedBy
|
gptkb:Novo_Nordisk
|
|
gptkbp:duration
|
up to 24 hours
|
|
gptkbp:eliminationHalfLife
|
5-7 hours
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:hasMolecularFormula
|
C267H402N64O76S6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
insulin detemir
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to insulin receptor
|
|
gptkbp:notable_for
|
lower risk of nocturnal hypoglycemia than NPH insulin
less weight gain than NPH insulin
|
|
gptkbp:onset
|
1-2 hours
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:postTranslationalModification
|
myristic acid attached to lysine at B29
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:product
|
recombinant DNA
|
|
gptkbp:PubChem_CID
|
DB01309
16134922
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
weight gain
injection site reactions
|
|
gptkbp:storage
|
refrigerate
|
|
gptkbp:UNII
|
GFX7QIS1II
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
type 1 diabetes
|
|
gptkbp:bfsParent
|
gptkb:Insulin_ultralente
gptkb:Levemir
|
|
gptkbp:bfsLayer
|
7
|